<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04266613</url>
  </required_header>
  <id_info>
    <org_study_id>TGRP03-US003</org_study_id>
    <nct_id>NCT04266613</nct_id>
  </id_info>
  <brief_title>TruGraf® Testing in High-Risk Kidney Transplant Recipients</brief_title>
  <official_title>Molecular Biomarkers in Renal Transplant Recipients at Higher Risk of Acute Rejection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transplant Genomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Transplant Genomics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study to evaluate TruGraf® testing in high immune risk kidney
      transplant recipients. TruGraf is the first and only non-invasive test approved by Medicare
      to rule out silent rejection in stable kidney transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 20, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Utility of TruGraf Results</measure>
    <time_frame>1 year</time_frame>
    <description>Percent of total number of TruGraf results that the PI identified as having clinical utility</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of TruGraf Results</measure>
    <time_frame>1 year</time_frame>
    <description>Percent of total number of TruGraf results that the PI identified as being correlated to other clinical results obtained through the standard of care</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>All Subjects Enrolled</arm_group_label>
    <description>High immune risk transplant recipients who are undergoing routine management under current standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>TruGraf® Testing</intervention_name>
    <description>5 mL collection PAXgene blood sample</description>
    <arm_group_label>All Subjects Enrolled</arm_group_label>
    <other_name>Peripheral blood gene expression profiling</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Kidney transplant recipients with high immune risk who are undergoing routine management
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High immune risk kidney transplant recipients defined by one of the following
             criteria: either a positive pretransplant donor specific anti-human leukocyte antigen
             (HLA) antibody, or a pre-transplant panel reactive antibody &gt;75%.

          -  Recipient of a primary or subsequent deceased-donor or living donor kidney
             transplantation.

          -  Stable serum creatinine (current serum creatinine &lt;2.3 mg/dl, &lt;20% increase compared
             to the average of the previous 3 serum creatinine levels).

          -  Kidney transplant patients who are at least 30 days post-transplant.

        Exclusion Criteria:

          -  Need for combined organ transplantation with an extra-renal organ and/or islet cell
             transplant.

          -  Recipients who do not meet criteria of high-immune risk.

          -  Recipients of previous non-renal solid organ and/or islet cell transplantation.

          -  Infection with HIV.

          -  Infection with BK.

          -  Patients that have nephrotic proteinuria (urine protein &gt;3 gm/day).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Holman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Transplant Genomics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Methodist Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Marsh CL, Kurian SM, Rice JC, Whisenant TC, David J, Rose S, Schieve C, Lee D, Case J, Barrick B, Peddi VR, Mannon RB, Knight R, Maluf D, Mandelbrot D, Patel A, Friedewald JJ, Abecassis MM, First MR. Application of TruGraf v1: A Novel Molecular Biomarker for Managing Kidney Transplant Recipients With Stable Renal Function. Transplant Proc. 2019 Apr;51(3):722-728. doi: 10.1016/j.transproceed.2019.01.054. Epub 2019 Jan 26.</citation>
    <PMID>30979456</PMID>
  </reference>
  <reference>
    <citation>First MR, Peddi VR, Mannon R, Knight R, Marsh CL, Kurian SM, Rice JC, Maluf D, Mandelbrot D, Patel A, David J, Schieve C, Lee D, Lewis P, Friedewald JJ, Abecassis MM, Rose S. Investigator Assessment of the Utility of the TruGraf Molecular Diagnostic Test in Clinical Practice. Transplant Proc. 2019 Apr;51(3):729-733. doi: 10.1016/j.transproceed.2018.10.024. Epub 2018 Dec 11.</citation>
    <PMID>30979457</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

